By Hendra Lukman 
New findings from the phase 2 EVITA clinical trial suggest that vitamin C supplementation may offer significant benefits for individuals with precancerous blood conditions and early-stage blood cancers. The randomized, double-blind, placebo-controlled study, conducted by the Van Andel Institute-Stand Up To Cancer® Epigenetics Dream Team, revealed that daily oral vitamin C not only reduced adverse events but also demonstrated a potential to improve long-term survival rates in a vulnerable patient population. The results, published in the esteemed American Cancer Society journal CANCER, are generating cautious optimism among researchers and clinicians involved in the fight against hematological malignancies.
The EVITA trial, which enrolled 109 patients diagnosed with clonal cytopenia of undetermined significance (CCUS) or myelodysplastic syndrome (MDS), represents a pioneering effort to investigate the role of oral vitamin C in a preventative or early-intervention context for blood cancers. These conditions are particularly concerning as they can progress to acute myeloid leukemia (AML), an aggressive and often challenging-to-treat form of blood cancer. For many patients with CCUS and MDS, particularly older adults who are disproportionately affected by these conditions, current treatment options are limited to vigilant monitoring or, in the case of MDS, potentially a stem cell transplant that is not feasible for all. The EVITA trial directly addressed this unmet clinical need by exploring a readily accessible and potentially impactful intervention.
Vitamin C’s Multifaceted Role in Health and Cancer
Vitamin C, or ascorbic acid, is an essential nutrient renowned for its crucial roles in maintaining a robust immune system, facilitating wound healing, and acting as a potent antioxidant that protects cells from damage caused by free radicals. Beyond these well-established functions, emerging research over the past decade has illuminated vitamin C’s more complex involvement in cellular processes, particularly its influence on gene activity and normal cell development. This deeper understanding has spurred investigations into its therapeutic potential in various disease contexts, including cancer.
A key discovery in this area involves the enzyme TET2, which plays a critical role in preventing cancerous growth by regulating gene expression – essentially controlling which genes are turned "on" or "off." Vitamin C has been found to support the activity of TET2, thereby helping to maintain normal patterns of gene regulation. Mutations in the TET2 gene are frequently observed in leukemia and related blood disorders. When TET2 function is impaired, abnormal cells can proliferate unchecked, creating an environment conducive to cancer development. This biological mechanism provides a compelling rationale for exploring vitamin C as a means to counteract the cellular dysregulation that precedes the onset of leukemia.
The EVITA Trial: Design and Key Findings
The EVITA study was meticulously designed to rigorously assess the effects of vitamin C supplementation. Participants were randomly assigned to receive either 1,000 mg of oral vitamin C daily for one year or a placebo. The study employed a double-blind, placebo-controlled methodology, meaning neither the participants nor the researchers administering the treatment knew who was receiving the active supplement or the placebo. This gold standard approach in clinical research is crucial for minimizing bias and ensuring that any observed effects are attributable to the vitamin C itself rather than psychological factors or observer expectations.
The trial’s primary endpoints were designed to evaluate safety and tolerability, alongside changes in immune signaling molecules known as cytokines, which are indicative of inflammation and immune response. A significant finding was that patients who received vitamin C experienced fewer adverse events throughout the study and its follow-up period compared to the placebo group. Furthermore, the vitamin C supplementation led to changes in cytokine levels that were associated with more favorable outcomes, suggesting a positive influence on inflammation-related processes that can drive the growth and progression of abnormal blood cells.
While the vitamin C supplementation did not significantly alter the rate at which abnormal blood cells expanded during the study, an exploratory analysis revealed a particularly encouraging trend. Participants who received vitamin C were significantly more likely to be alive after approximately three years of follow-up than those who received the placebo. This potential survival benefit, though preliminary, is a critical finding that warrants further investigation in larger trials.
A Glimpse into the Future of Cancer Interception
The implications of the EVITA trial extend to a growing emphasis on "cancer interception"—the strategy of intervening early in the disease process, before cancer becomes fully established. Peter A. Jones, Ph.D., D.Sc. (hon), a distinguished professor at Van Andel Institute and co-corresponding author of the research, expressed his excitement about the potential of this simple intervention. "We are tremendously excited and cautiously optimistic that our results could one day translate into a simple way to improve care and outcomes for people with pre-leukemia disorders," Dr. Jones stated. "Our approach reflects a growing emphasis on cancer interception—intervening before cancer becomes established. We are working to build on the trial findings by exploring how exactly vitamin C interacts with pre-cancerous cells, including the idea that it may help restore normal epigenetic function in blood cells at risk of becoming leukemia."
This sentiment was echoed by Kirsten Grønbæk, M.D., Ph.D., a leading hematologist at the University of Copenhagen and co-leader of the VAI-SU2C Epigenetics Dream Team, who spearheaded the international research effort. "These exciting preliminary findings lay the groundwork for a larger clinical trial to explore vitamin C as a possible way to improve patient outcomes," Dr. Grønbæk commented. "It is too early to make definitive recommendations based on our results, but we are hopeful that a more expansive study will provide further insights."
Addressing a Critical Unmet Need
The conditions studied in EVITA, CCUS and MDS, represent a significant clinical challenge. CCUS is characterized by the presence of specific genetic mutations in blood-forming cells, leading to an increased risk of developing leukemia without any clear cause. MDS, on the other hand, is a group of disorders in which immature blood cells in the bone marrow do not mature properly, leading to a shortage of healthy blood cells. Both conditions are more prevalent in older adults, a demographic that often has co-existing medical conditions that preclude more aggressive treatments like stem cell transplantation.
Currently, there is no approved therapy that can reliably prevent CCUS from progressing to leukemia. For patients with MDS, while stem cell transplantation can be curative, it is a high-risk procedure and not suitable for many. This leaves a considerable number of individuals in a precarious state of "watchful waiting," where their disease is monitored for signs of progression, a situation described as frustrating by clinicians.
Casey O’Connell, M.D., FACP, the Lawrence and Jane Kelly Chair in Hematology at the University of Southern California and lead clinician at USC’s trial location, highlighted this clinical dilemma. "The standard approach for patients with pre-cancer blood disorders is to monitor their blood cell counts over time. This is, understandably, very frustrating—no one wants to hear that they have a condition that increases leukemia risk but there’s nothing that can be done other than watch and wait," Dr. O’Connell remarked. "The EVITA trial took on this challenge by exploring vitamin C’s potential to address the underlying factors that drive leukemia development."
A Historical Perspective on Vitamin C and Cancer Research
The exploration of vitamin C’s role in cancer is not new; it has been a subject of scientific inquiry for over seven decades. Early studies yielded inconsistent results, often due to variations in methodology, dosage, and the type of cancer investigated. For a significant period, the evidence remained inconclusive, leading to skepticism about its therapeutic potential.
However, advancements in research technologies over the past decade have provided a more nuanced understanding of vitamin C’s biological functions. Beyond its antioxidant and immune-supportive roles, scientists have uncovered its critical involvement in epigenetic regulation—the control of gene expression without altering the underlying DNA sequence. This deeper insight has revitalized interest in vitamin C as a potential therapeutic agent, particularly in contexts where epigenetic dysregulation contributes to disease.
Experiments utilizing cancer models have further bolstered the case for vitamin C’s protective effects. These studies have demonstrated that vitamin C supplementation can interfere with cellular changes associated with cancer and potentially slow the progression of leukemia. Notably, the most pronounced effects were observed when vitamin C was introduced at an early stage, before cancer had become fully established, aligning with the interception strategy explored in EVITA.
Building Towards the Future: The EVITA Trial’s Place in a Chronology of Research
The EVITA trial did not emerge in a vacuum. It was preceded by crucial foundational work. Before launching the phase 2 trial, the VAI-SU2C Epigenetics Dream Team conducted a pilot clinical study in 2016. This initial study was designed to determine whether oral vitamin C supplementation could effectively increase blood concentrations of the nutrient in a patient population. The positive outcomes of this pilot study provided the necessary evidence to support the feasibility of an oral supplementation approach and encouraged the researchers to proceed with the larger phase 2 EVITA trial, which commenced in 2017.
"This early work was critical because it offered a foundation from which to develop the present trial," stated Stine Ulrik Mikkelsen, M.D., Ph.D., the study’s first author and a clinician researcher in Dr. Grønbæk’s laboratory. "Vitamin C is important because it is involved in a range of biological functions, including the activity of enzymes that regulate normal cell function."
The EVITA trial itself was conducted at four reputable hospitals: Copenhagen University Hospital-Rigshospitalet, Copenhagen University Hospital-Herlev, Aalborg University Hospital, and Keck Hospital of the University of Southern California, underscoring the collaborative and multi-institutional nature of this significant research endeavor.
What makes EVITA particularly notable is its innovative approach. Unlike earlier studies that often focused on intravenous vitamin C administration and primarily investigated solid tumors, EVITA evaluated a daily oral dose of vitamin C in patients with precancerous blood disorders or lower-risk myeloid cancers. This focus on oral administration makes the potential intervention more accessible and practical for widespread clinical use.
Broader Impact and Future Directions
The findings from the EVITA trial offer a compelling rationale for further investigation into vitamin C as a therapeutic strategy for individuals at high risk of developing leukemia. The observed reduction in adverse events suggests a favorable safety profile, and the potential survival benefit, though requiring confirmation, is highly significant.
Researchers are continuing to meticulously analyze the EVITA data to gain a deeper understanding of the biological mechanisms that may underlie the observed improvements in survival. This includes further exploring how vitamin C might influence immune responses and cellular processes that are critical in preventing the transformation of precancerous cells into overt leukemia.
The logical next step in this research trajectory is a larger, phase 3 clinical trial. Such a trial would involve a greater number of participants and be designed to definitively confirm whether vitamin C supplementation can reliably improve outcomes, including survival rates, for individuals with precancerous blood disorders and early-stage blood cancers. The success of a phase 3 trial would pave the way for vitamin C to become an established component of care for these patient populations, offering a much-needed, accessible intervention in a field where treatment options are often limited.
The collaborative efforts of institutions such as the Van Andel Institute, Stand Up To Cancer®, the University of Copenhagen, and the various participating hospitals, along with funding from organizations like the Danish Cancer Society and Greater Copenhagen Health Science Partners, have been instrumental in advancing this research. Their continued commitment is vital as scientists work to translate these promising preliminary findings into tangible benefits for patients facing the threat of leukemia.
The research team also included a comprehensive list of contributing authors from the University of Copenhagen, Copenhagen University Hospital-Rigshospitalet, Van Andel Institute, Johns Hopkins University, Copenhagen University Hospital-Herlev, and Aalborg University Hospital, highlighting the extensive collaboration involved in this significant scientific endeavor.
